Invokamet Xr

Active Ingredient(s): Canagliflozin + Metformin Hydrochloride
FDA Approved: * September 20, 2016
Pharm Company: * JANSSEN PHARMS
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Invokamet Xr Overview

Canagliflozin (trade name Invokana or Sulisent) is a medication used for the treatment of type 2 diabetes.[1][2] It is of the gliflozin class or subtype 2 sodium-glucose transport (SGLT-2) inhibitors class. This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to sulfonylurea derivatives and insulin.[3] In 2017, the FDA concluded that canagliflozin causes an increased risk of leg and foot amputations.[4] The FDA began requiring a Boxed Warning to be ad...

Read more Invokamet Xr Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Canagliflozin

Recent Invokamet Xr Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Invokamet Xr: (4 results)

Sorted by National Drug Code

• 50458-940 Invokamet XR Oral Tablet, Film Coated, Extended Release by Janssen Pharmaceuticals, Inc.
• 50458-941 Invokamet XR Oral Tablet, Film Coated, Extended Release by Janssen Pharmaceuticals, Inc.
• 50458-942 Invokamet XR Oral Tablet, Film Coated, Extended Release by Janssen Pharmaceuticals, Inc.
• 50458-943 Invokamet XR Oral Tablet, Film Coated, Extended Release by Janssen Pharmaceuticals, Inc.

Drugs with one or more similar ingredients: (23 results)

Possibly related Invokamet Xr Topics: